Solid Biosciences to Reduce its Work Force by Approximately One Third; Announces Executive Changes
In conjunction, Chief Operating Officer Alvaro Amorrortu, M.B.A. and Chief Medical Officer Jorge Quiroz, M.D., M.B.A. will depart the company but will continue as advisors to Solid. The corporate changes implemented will result in a reduction in corporate expenses and, based on the company's current operating plans, are expected to extend the cash runway into 2021.